Koziol D E, Kurtzman G, Ayub J, Young N S, Henderson D K
Hospital Epidemiology Service, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892.
Infect Control Hosp Epidemiol. 1992 Jun;13(6):343-8. doi: 10.1086/646542.
To assess the potential for nosocomial spread of parvovirus B19 from a chronically infected patient.
Employees exposed to the index case and control (unexposed) employees were evaluated by baseline and follow up parvovirus B19 serologies and hematologic assessments, and completed baseline and follow up epidemiologic questionnaires.
A chronically infected patient was hospitalized on a hematology ward in a research referral hospital for 3.5 weeks prior to a diagnosis of parvovirus B19 infection and the institution of isolation precautions.
Sera were screened for parvovirus B19 DNA (dot blot analysis), and IgG and IgM anti-B19 antibodies (capture immunoassay). Hematologic assessment included CBC, differential, and reticulocyte count.
The index case had parvovirus B19 DNA at approximately 10(6) genome copies per ml of serum, elevated IgM and low levels of IgG B19 antibodies. Of the 21 exposed staff, 11 (52%) had IgG B19 antibodies and were immune; of the 8 unexposed staff, 6 (75%) had IgG B19 antibodies. No employees developed IgM B19 antibodies, B19 DNA, hematologic abnormalities, or clinical symptoms.
In contrast to reports of documented nosocomial transmission of B19 parvovirus from patients in transient aplastic crisis, nosocomial transmission did not occur--even in the absence of isolation precautions--presumably from the lower level of B19 viremia in our chronically infected (rather than acutely infected) patient.
评估B19微小病毒在一名慢性感染患者中发生医院内传播的可能性。
对接触过该索引病例的员工和对照(未接触过)员工进行基线和随访时的B19微小病毒血清学及血液学评估,并完成基线和随访时的流行病学调查问卷。
一名慢性感染患者在一家研究型转诊医院的血液科病房住院3.5周,之后才诊断出B19微小病毒感染并采取隔离预防措施。
对血清进行B19微小病毒DNA筛查(斑点印迹分析)以及IgG和IgM抗B19抗体检测(捕获免疫测定)。血液学评估包括全血细胞计数、分类计数和网织红细胞计数。
索引病例血清中B19微小病毒DNA含量约为每毫升10(6)个基因组拷贝,IgM升高,IgG B19抗体水平较低。在21名接触过的工作人员中,11人(52%)有IgG B19抗体且具有免疫力;在8名未接触过的工作人员中,6人(75%)有IgG B19抗体。没有员工出现IgM B19抗体、B19 DNA、血液学异常或临床症状。
与有记录的B19微小病毒在再生障碍性危象患者中发生医院内传播的报道相反,即使没有采取隔离预防措施,医院内传播也未发生,推测原因是我们的慢性感染(而非急性感染)患者的B19病毒血症水平较低。